Veracyte to highlight Decipher clinical data at ASCO

By LabPulse.com staff writers

May 25, 2021 -- Veracyte plans to highlight results from two studies that show its Decipher prostate genomic classifier (GC) offers prognostic information that can help clinicians tailor treatment to men with prostate cancer. The study findings will be presented at the virtual American Society of Clinical Oncology (ASCO) to be held in June.

The two studies are the Validation Study on the Impact of Decipher Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM) and the Swiss Group for Clinical Cancer Research (SAKK) 09/10 trial.

The first study shows that Veracyte's Decipher GC can predict aggressive prostate cancer in Black men with the same accuracy as in non-Black men; the second shows that men with a Decipher high-risk score who are undergoing salvage radiotherapy alone are more than twice as likely as those with a Decipher low- or intermediate-risk score to experience biochemical progression, according to the firm.

Veracyte completes Decipher acquisition for $600M
Veracyte has completed a $600 million cash deal to acquire Decipher Biosciences, expanding its position in the genomics-driven cancer diagnostics...
Veracyte to acquire Decipher Biosciences
Veracyte has announced plans to acquire Decipher Biosciences in a move that unites Veracyte's position in genomic cancer diagnostics with Decipher's activities...
Bayer and Veracyte team up on thyroid cancer genomic profiling
Bayer and Veracyte are planning to work together on the genetic testing of patients with metastatic thyroid cancer. They will target patients whose disease...
Veracyte touts study on Prosigna breast cancer test
Veracyte said the genomic underpinnings of its Prosigna breast cancer gene signature assay, particularly its relative weighting of genes predicting tumor...
Veracyte initiates study on breast cancer genomic tests
Veracyte has started a European consensus study that will explore the medical utility of multiple breast cancer genomic tests. Coordinated by Dr. Giuseppe...

Copyright © 2021 LabPulse.com

Last Updated ls 5/25/2021 3:23:18 PM